MedTrace Logo

Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

NCT00485368 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2007-06-13

No results posted yet for this study

Summary

The purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that comes out of the heart and supplies blood to the body. We know that in people with Marfan Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. This enlargement of the aorta can be very serious. We know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This type of drug has never been tried in people with Marfan Syndrome.

Conditions

  • Marfan Syndrome

Interventions

DRUG

Coversyl (perindopril)

Sponsors & Collaborators

  • Baker Heart Research Institute

    collaborator OTHER

  • The Alfred

    collaborator OTHER

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • Bronwyn A Kingwell, PhD · Baker Heart Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2006-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00485368 on ClinicalTrials.gov